Global benign prostatic hyperplasia market to expand at 8% CAGR
The value of the global therapeutics market for benign prostatic hyperplasia (BPH) will rise from just over $2 billion in 2014 to approximately $4.9 billion by 2024, representing a compound annual growth rate (CAGR) of 8.23%.
According to research and consulting firm GlobalData’s latest report, across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, the USA will continue its current dominance, accounting for 65% of the global arena by 2024.
Valentina Gburcik, GlobalData’s director of cardiovascular and metabolic disorders, states that three novel therapies will contribute to the growth of the BPH therapeutics market, including the launch of Nymox Pharmaceutical’s (Nasdaq: NYMX) novel first-in-class therapy, NX-1207 (fexapotide triflutate), in the USA and Europe in 2017 and 2019, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze